PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24.88%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other expenses reduction while AVXL shows 662.65% growth. Joel Greenblatt would examine efficiency.
-27.70%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-27.70%
Both companies reducing total costs. Martin Whitman would check industry trends.
-8.45%
Both companies reducing interest expense. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
27.70%
EBITDA growth 1.25-1.5x AVXL's 20.06%. Bruce Berkowitz would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
27.70%
Operating income growth exceeding 1.5x AVXL's 15.87%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-27.70%
Other expenses reduction while AVXL shows 325.38% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
117.18%
Tax expense growth while AVXL reduces burden. John Neff would investigate differences.
-117.18%
Net income decline while AVXL shows 19.95% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-117.27%
EPS decline while AVXL shows 19.35% growth. Joel Greenblatt would examine position.
-117.27%
Diluted EPS decline while AVXL shows 19.35% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.